Advice
The European Medicines Agency (EMA)’s Pharmacovigilance Risk Assessment Committee (PRAC) has recommended that the marketing, supply and authorisations of extended-release niacin/laropiprant medicines (Tredaptive®) be suspended across the EU. This follows an assessment of the available data related to safety concerns, and the conclusion by the Committee that the risks are greater than the benefits in adults with dyslipidaemia.
 
The SMC Advice has been removed from the website.

Medicine details

Medicine name:
nicotinic acid/laropiprant (Tredaptive)
SMC ID:
614/10
Indication:
dyslipidaemia
Pharmaceutical company
MSD
BNF chapter
Cardiovascular system
Submission type
Full
Status
Date advice published:
10 May 2010